Using AI to Become Pharma’s Next Superhero
PodcastFor Nina Binetti, Vice President of Product and Life Science Marketing at Viz.ai, there is much reason for excitement about...
Harness the power of AI to accelerate patient access to therapy—enabling care teams to deliver the right care to the right patients at the right time.
Accelerate access to care and prevent drop out
Artificial intelligence is changing how healthcare is being delivered—biopharma and medtech companies are adapting their go-to-market strategy for therapies to reach more patients who need them—when they need them.
AI, coupled with novel clinical workflow tools, is enabling healthcare providers to detect disease earlier, unite patients with specialists, improve outcomes, and prevent patient leakage—all in real time and from the palm of their hands. AI is revolutionizing healthcare—biopharma and medtech companies are changing, are you?
Viz.ai is being used today in over 1,500+ hospitals and at top integrated delivery networks (IDNs) in the United States and serves one patient every 11 seconds. We empower >45,000 clinicians and healthcare providers to detect diseases earlier, address barriers in the patient journey, and get patients to the treatments they need to optimize outcomes—backed by real-world evidence in over 100 clinical publications.
3x
increase in patients to specialist
50%
up to
of follow-ups are not completed
Care pathways
Close gaps in patient care by minimizing the number of patients getting lost in the system.
increase trial enrollment rates by
3x
Accelerate trial enrollment
Increase clinical trial enrollment with efficient identification and recruitment capabilities.
Learn moreGet ready, pharma! Download the guide for 4 use cases that challenge everything you thought possible
Download the whitepaperIn August 2023, Viz.ai received De Novo approval by the FDA for an artificial intelligence (AI) detection algorithm designed to detect hypertrophic cardiomyopathy (HCM), creating a new regulatory category for cardiovascular machine learning-based notification software. The deployment of this algorithm was made possible through financial support from Bristol Myers Squibb.
The Viz HCM algorithm uses AI to analyze ECGs and flag any patterns that suggest HCM. It ingests 12-lead ECG recordings, and the analyzed results are made available on Viz’ mobile ECG viewer, facilitating communication and image sharing with the entire cardiac care team to expedite patient triage for additional diagnostic workup.
Viz HCM is one of 13 FDA-cleared AI algorithms on the enterprise-wide, clinically validated Viz.ai platform, which has been demonstrated to increase access to treatment and improve patient outcomes.
Trusted by
1500+
hospitals with users across many specialties and disease areas
Screening 1 patient every
12
seconds
>90%
of alerts viewed within 5 minutes
Backed by robust clinical evidence with
100+
publications and abstracts